fda guideline for the monitoring of clinical investigations
by providing additional guidance to facilitate sponsors' implementation of risk-based monitoring. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day. You may submit either electronic or written comments on Agency guidances at any time as follows: Submit electronic comments in the following way: 1061, Rockville, MD 20852. A Notice by the Food and Drug Administration on 03/15/2019. 66, Room 5431, Silver Spring, MD 209930002; or the Office of Clinical Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. The US Food and Drug Administration (FDA) requires that clinical trial sponsors "provide oversight to ensure adequate protection of the rights, welfare, and safety of human subjects and the quality of the data submitted to FDA." [US FDA 2019] This has traditionally been accomplished through onsite monitoring visits and 100% source data verificat. 17 April 2023 The CRSO regulatory blog highlights key trends and regulatory developments in clinical research. This draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The announcement of the guidance is published in the the material on FederalRegister.gov is accurately displayed, consistent with establishing the XML-based Federal Register as an ACFR-sanctioned Before sharing sensitive information, make sure you're on a federal government site. to the courts under 44 U.S.C. This template provides a recommended structure for a Clinical Monitoring Plan (CMP) as well as draft language and other guidance It is to be used as a starting point for preparing a Clinical Monitoring Plan Audience/User: Clinical Research Associates (CRAs) or Principal Investigators (PI) responsible for preparing a Clinical Monitoring Plan Register documents. https://www.federalregister.gov/d/2019-04814, MODS: Government Publishing Office metadata, https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf, https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm, https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm269919.pdf. A Risk-Based Approach to Monitoring of Clinical Investigations Establishing national surveillance system for antimicrobial consumption informational resource until the Administrative Committee of the Federal Dockets Management Staff (HFA305), Food and Drug Administration, 5630 Fishers Lane, Rm. Sheila Brown, Office of Clinical Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. edition of the Federal Register. Search for FDA Guidance Documents, Guidance For IRBs, Clinical Investigators, and Sponsors, Recalls, Market Withdrawals and Safety Alerts, Search General and Cross-Cutting Topics Guidance Documents, FDA Inspections of Clinical Investigators. This guidance finalizes the draft guidance entitled A Risk-Based Approach to Monitoring of Clinical Investigations: Questions and Answers, issued on March 15, 2019 (84 FR 9531). and insert the docket number, found in brackets in the heading of this document, into the Search box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. An official website of the United States government, : Rockville, MD 20852. Search for FDA Guidance Documents, Recalls, Market Withdrawals and Safety Alerts, Search General and Cross-Cutting Topics Guidance Documents, A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers. Rather, guidances describe the Agency's current thinking on a topic and should . FDA outlines risk-based approach to monitoring clinical trials requirements of the applicable statutes and regulations. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes, regulations, or both. Computer Issues. If unable to submit comments online, please mail written comments to: Dockets Management Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, Office of the Commissioner, Office of Clinical Policy and Programs, Office of Clinical Policy, Office of Good Clinical Practice, An official website of the United States government, : The guidance contains recommendations on planning a monitoring approach, developing the content of a monitoring plan, and addressing and communicating monitoring results. Drugs. Until the ACFR grants it official status, the XML Confidential SubmissionsTo submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. %PDF-1.6 % Clinical investigation monitoring is a quality control tool for determining whether investigation activities are being carried out as planned, so that, among other things, deficiencies can be identified and corrected. (vi) The name and title of the person responsible for monitoring the conduct and progress of the clinical investigations. Only official editions of the You should submit two copies total. Docket: Monitoring of clinical investigations; availability of guideline--FDA This feature is not available for this document. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Food and Drug Administration 71, Rm. 4 3 Guidance for Industry1 6 5 This draft guidance, when finalized, will represent the current thinking of the Food and Drug 7 Administration (FDA or Agency) on this topic. Psychedelic Drugs: Considerations for Clinical Investigations | FDA 202307687 Filed 41123; 8:45 am]. You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5)). Additionally, editorial changes were made to improve clarity. the current document as it appeared on Public Inspection on and services, go to mona.shing@fda.hhs.gov; This guidance contains recommendations on planning a monitoring approach, developing the content of a monitoring plan, and addressing and communicating monitoring results. 1. This draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). will be posted to the docket unchanged. Follow the instructions for submitting comments. This document has been published in the Federal Register. Sheila.Brown@fda.hhs.gov; Effective implementation of risk-based monitoring of clinical investigations, including the prioritization of monitoring and other oversight activities directed at processes and procedures critical for human subject protection and maintaining data integrity, should help maximize the quality of a clinical investigation. If unable to submit comments online, please mail written comments to: Dockets Management From choosing baby's name to helping a teenager choose a college, you'll make . 5431, Silver Spring, MD 20993-0002, 301-796-5666, CDRHClinicalEvidence@fda.hhs.gov; Sheila Brown, Office of Good Clinical Practice, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. Complexity of the study. The FDA is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the . The Food and Drug Administration (FDA) recently issued first-of-its kind draft guidance for investigational new drug (IND) applications involving psychedelic drugs. https://www.federalregister.gov/d/2023-07687, MODS: Government Publishing Office metadata, https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf, https://www.fda.gov/regulatory-information/search-fda-guidance-documents, https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs, https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances, https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/guidance-documents-medical-devices-and-radiation-emitting-products. All comments should be identified with the title of the guidance. 0 establishing the XML-based Federal Register as an ACFR-sanctioned Published Apr 11, 2023 + Follow 11 April 2023: https://www.fda.gov/media/121479/download EXECUTIVE SUMMARY What is the purpose of the risk assessment, and should sponsors document their. 5. Register (ACFR) issues a regulation granting it official legal status. The previously approved collections of information are subject to review by OMB under the PRA. https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on Miscellaneous. PDF Establishing Risk-Based Monitoring within a Quality-Based System "Best Clinical investigation monitoring is a quality control tool for determining whether investigation activities are being carried out as planned. 71, Rm. You can use an alternative approach if it satisfies the requirements of the Send one self-addressed adhesive label to assist that office in processing your requests. Clinical investigation monitoring is a quality control tool for determining whether investigation activities are being carried out as planned. PDF Guidance for Industry Oversight of Clinical Investigations A Risk This guidance expands on the guidance for industry entitled Oversight of Clinical InvestigationsA Risk-Based Approach to Monitoring (August 2013) (the RBM Guidance) by providing additional guidance to facilitate sponsors' implementation of risk-based monitoring. 1. The .gov means its official.Federal government websites often end in .gov or .mil. headings within the legal text of Federal Register documents. CDER/CBER, June 2023. 35013521) is not required for this guidance. If you need further assistance, please go to Contact FDA. 3. Office of Training and Communications Division of Drug Information10903 New Hampshire Avenue Silver Spring, MD 20993, BiosimilarsClinical Antimicrobial CMC-Chemistry, Clinical Medical Clinical Pharmacology CMC - Microbiology Combination Products (Drug/Device/Biologic) Current Good Manufacturing Practices/Compliance Drug SafetyElectronic SubmissionsGeneric Drug Good Review Practices ICH INDIndustry LettersLabeling Modernization Act OTC Pharmacology/ToxicologyProcedural Small Entity Compliance GuidesUser Fee, Aerosol Steroid Product Safety Information in Prescription Drug Advertising and Promotional Labeling (I), Consumer-Directed Broadcast Advertisements (I), Industry-Supported Scientific and Educational Activities (I), Product Name Placement, Size, and Prominence in Advertising & Promotional Labeling, Help-Seeking and Other Disease Awareness Communications by or on Behalf of Drug and Device Firms (I), Accelerated Approval Products -- Submission of Promotional Materials (I), Brief Summary: Disclosing Risk Information in Consumer-Directed Print Advertisements(I), Direct-to-Consumer Television Advertisements -- FDAAA DTC Television Ad Pre-Dissemination Review Program, Presenting Risk Information in Prescription Drug and Medical Device Promotion (I), Promoting Medical Products in a Changing Healthcare Environment; Medical Product Promotion by Healthcare Organizations or Pharmacy Benefits Management Companies (PBMs) (I), Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations (Revised) (I), Corticosteroids, Dermatologic (topical) In Vivo (I), Dissolution Testing of Immediate Release Solid Oral Dosage Forms (I), Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations (I), Food-Effect Bioavailability and Fed Bioequivalence Studies (I), Metaproterenol Sulfate and Albuterol Metered Dose Inhalers In Vitro (I), Statistical Approaches to Establishing Bioequivalence (I), Waiver of In Vivo Bioavailability and Bioequivalence Studies for Imediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System (I), Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action (I), Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product, Scientific Considerations in Demonstrating Biosimilarity to a Reference Product, Guidance for Industry on Biosimilars: Q & As Regarding Implementation of the BPCI Act of 2009, Changes to an Approved Application for Specified Biotechnology and Specified Synthetic Biological Products (I), Changes to an Approved NDA or ANDA (Revised) (I), Changes to an Approved NDA or ANDA: Questions and Answers (I), Changes to an Approved New Drug Application or Abbreviated New Drug Application; Specifications -Use of Enforcement Discretion for Compendial Changes (I), Container Closure Systems for Packaging Human Drugs and Biologics (I), Demonstration of Comparability of Human Biological Products Including Therapeutic Biotechnology Derived Products (I), Development of New Stereoisomeric Drugs (I), Drug Master Files for Bulk Antibiotic Drug Sustances (I), Environmental Assessment of Human Drug and Biologics Applications (I), Format and Content for the CMC Section of an Annual Report (I), Format and Content of the Microbiology Section of an Application* (I), Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting (I), IND Meetings for Human Drugs and Biologics; Chemistry, Manufacturing, and Controls Information (I), INDs for Phase 2 and 3 Studies; Chemistry, Manufacturing, and Controls Information (I), Monoclonal Antibodies Used as Reagents in Drug Manufacturing (I), Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products -- Chemistry, Manufacturing, and Controls Documentation (I), PAC-ALTS: Postapproval Changes - Analytical Testing Laboratory Sites (I), Residual Drug in Transdermal and Related Drug Delivery Systems (I), Size of Beads in Drug Products Labeled for Sprinkle, Submitting Documentation for the Manufacturing of and Controls for Drug Products* (I), Submitting Samples and Analytical Data for Methods Validation* (I), Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Products (I), SUPAC-IR Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (I), SUPAC-IR/MR: Immediate Release and Modified Release Solid Oral Dosage Forms, Manufacturing Equipment Addendum (I), SUPAC-MR: Modified Release Solid Oral Dosage Forms: Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (I), SUPAC-SS - Nonsterile Semisolid Dosage Forms; Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation (I), The Sourcing and Processing of Gelatin to Reduce the Potential Risk Posed by Bovine Spongiform (I), Validation of Chromatographic Methods -- Reviewer's Guidance (I), Analytical Procedures and Methods Validation (I), Assay Development for Immunogenicity Testing of Therapeutic Proteins (I), CMC Postapproval Manufacturing Changes Reportable in Annual Reports (I), Comparability Protocols - Chemistry, Manufacturing, and Controls Information (I), Drugs, Biologics, and Medical Devices Derived From Bioengineered Plants for Use in Humans and Animals (I), Interpreting Sameness of Monoclonal Antibody Products Under the Orphan Drug Regulations (I), Limiting the Use of Certain Phthalates as Excipients in CDER-Regulated Products, Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation (I), Metered Dose Inhalers (MDI) and Dry Powder Inhalers (DPI) Drug Products (I), Non-Penicillin Beta-Lactam Risk Assessment: A CGMP Framework, Regulatory Classification of Pharmaceutical Co-Crystals, Submitting Supporting Chemistry Documentation in Radiopharmaceutical Drug Applications*, SUPAC-SS: Nonsterile Semisolid Dosage Forms Manufacturing Equipment Addendum (I), Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation, Antiretroviral Drugs Using Plasma Human Immunodeficiency Virus Ribonucleic Acid Measurements -Clinical Considerations for Accelerated and Traditional Approval (I), Antiviral Product Development -Conducting and Submitting Virology Studies to the Agency, Antibacterial Drug Products: Use of Noninferiority Trials to Support Approval, Clinical Development and Labeling of Anti-Infective Drug Products (I), Clinical Evaluation of Anti-Infective Drugs (Systemic) (I), Influenza: Developing Drugs for Treatment and/or Prophylaxis, Role of HIV Drug Resistance Testing in Antiretroviral Drug Development (I), Acute Bacterial Exacerbation of Chronic Bronchitis in Patients with COPD; Developing Antimicrobial Drugs for Treatment (I), Acute Bacterial Meningitis; Developing Antimicrobial Drugs for Treatment (I), Acute Bacterial Otitis Media: Developing Drugs for Treatment (I), Acute Bacterial Sinusitis: Developing Drugs for Treatment (I), Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment, Acute or Chronic Bacterial Prostatitis; Developing Antimicrobial Drugs for Treatment (I), Acute Otitis Media; Developing Antimicrobial Drugs for Treatment (I), Bacterial Vaginosis; Developing Antimicrobial Drugs for Treatment (I), Catheter-Related Bloodstream Infections - Developing Antimicrobial Drugs for Treatment (I), Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment, Community Acquired Pneumonia; Developing Antimicrobial Drugs for Treatment (I), Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment (I), Complicated Urinary Tract Infections: Developing Drugs for Treatment, Developing Antimicrobial Drugs -General Considerations for Clinical Trials (I), Developing Antimicrobial Drugs to Treat Inhalational Anthrax (Post-Exposure) (I), Empiric Therapy of Febrile Neutropenia; Developing Antimicrobial Drugs for Treatment (I), Evaluating Clinical Studies of Antimicrobials in the Division of Anti-Infective Drug Products (I), Helicobacter pylori-Associated Duodenal Ulcer Disease in Adults: Developing Drugs for Treatment (I), Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Developing Drugs for Treatment, Lyme Disease; Developing Antimicrobial Drugs for Treatment (I), Microbiological Data for Systemic Antibacterial Drug Products - Development, Analysis, and Presentation (I), Neglected Tropical Diseases of the Developing World: Developing Drugs for Treatment or Prevention, Nosocomial Pneumonia - Developing Antimicrobial Drugs for Treatment (I), Secondary Bacterial Infections of Acute Bronchitis - Developing Antimicrobial Drugs for Treatment (I), Smallpox (Variola) Infection: Developing Drugs for Treatment or Prevention (I), Streptococcal Pharyngitis and Tonsillitis; Developing Antimicrobial Drugs for Treatment (I), Uncomplicated and Complicated Skin and Skin Structure Infections; Developing Antimicrobial Drugs for Treatment (I), Uncomplicated Gonorrhea -- Developing Antimicrobial Drugs for Treatment (I), Uncomplicated Urinary Tract Infections - Developing Antimicrobial Drugs for Treatment (I), Vaccinia Virus -- Developing Drugs to Mitigate Complications From Smallpox Vaccination (I), Vuvlovaginal Candidiasis - Developing Antimicrobial Drugs for Treatment (I), Acceptance of Foreign Clinical Studies (I), Antianxiety Drugs -- Clinical Evaluation (I), Antidepressant Drugs -- Clinical Evaluation (I), Antiepileptic Drugs (adults and children) -- Clinical Evaluation (I), Calcium DTPA and Zinc DTPA Drug Products -- Submitting a New Drug Application (I), Cancer Drug and Biological Products - Clinical Data in Marketing Applications (I), Chronic Cutaneous Ulcer and Burn Wounds - Developing Products for Treatment (I), Clinical and Statistical Sections of an Application --Format and Content* (I), Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA) (I), Clinical Endpoints for the Approval of Cancer Drugs and Biologics (I), Collection of Race and Ethnicity Data in Clinical Trials for FDA Regulated Products (I), Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products (I), Developing Medical Imaging Drug and Biological Products, Part 1: Conducting Safety Assessments (I), Developing Medical Imaging Drug and Biological Products, Part 2: Clinical Indications (I), Developing Medical Imaging Drug and Biological Products, Part 3: Design, Analysis, and Interpretation of Clinical Studies (I), Development and Use of Risk Minimization Action Plans (I), Development of Vaginal Contraceptive Drugs (NDA) (I), Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes (I), Establishing Pregnancy Exposure Registries (I), Evaluating the Risks of Drug Exposure in Human Pregnancies, Evaluation of the Effects of Orally Inhaled and Intranasal Corticosteroids on Growth in Children (I), Exocrine Pancreatic Insufficiency Drug Products-Submitting New Drug Applications (I), FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products (I), FDA Requirements for Approval of Drugs to Treat Non-Small Cell Lung Cancer (I), Formatting, Assembling and Submitting New Drug and Antiobiotic Applications* (I), General Anesthetics -- Clinical Evaluation (I), General Considerations for the Clinical Evaluation of Drugs (I), General Considerations for the Clinical Evaluation of Drugs in Infants and Children (I), Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment (I), Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors: Exception from Informed Consent Requirements for Emergency Research, Hypnotic Drugs -- Clinical Evaluation (I), IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer (Revised) (I), Integration of Dose-Counting Mechanisms Into Metered-Dose Inhaler Drug Products (I), Internal Radioactive Contamination - Development of Decorporation Agents (I), Irritable Bowel Syndrome -- Clinical Evaluation of Products for Treatment, Levothyroxine Sodium Tablets -- In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing (I), Local Anesthetics -- Clinical Evaluation (I), MDI and DPI Drug Products -- Clinical Development and Programs (I), Oncologic Drugs Advisory Committee Discussion on FDA Requirements for Approval of New Drugs for Treatment of Colon and Rectal Cancer (I), Oncologic Drugs Advisory Committee Discussion on FDA Requirements for Approval of New Drugs for Treatment of Ovarian Cancer (I), Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims (I), Pediatric Use Supplements --Content and Format (I), Postmarketing Adverse Experience Reporting for Human Drugs and Licensed Biological Products; Clarification of What to Report (I), Postmarketing Reporting of Adverse Drug Experiences (I), Preparation of Investigational New Drug Products (Human and Animal) (I), Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products (I), Prussian Blue for Treatment of Internal Contamination With Thallium or Radioactive Cesium (I), Psychoactive Drugs in Infants and Children -- Clinical Evaluation (I), Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs (I), Study of Drugs Likely to be Used in the Elderly (I), Submission of Abbreviated Reports and Synopses in Support of Marketing Applications (I), Summary for New Drug and Antibiotic Applications -- Format and Content* (I), Systemic Lupus Erythematosus - Developing Drugs for Treatment (I), The Radioactive Drug Research Committee: Human Research Without An Investigational New Drug Application (I), Acne Vulgaris: Developing Drugs for Treatment (I), Allergic Rhinitis: Clinical Development Programs for Drug Products (I), Anti-Anginal Drugs -- Clinical Evaluation (I), Anti-Arrhythmic Drugs -- Clinical Evaluation, Antihypertensive Drugs -- Clinical Evaluation, Assessment of Abuse Potential of Drugs (I), Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment (I), Clinical Development Programs for Drugs, Devices, and Biological Products Intended for the Treatment of Osteoarthritis (OA) (I), Clinical Evaluation of Drugs for the Treatment of Congestive Heart Failure (I), Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics, Clinical Trial Sponsors on the Establishment and Operation of Clinical Trial Data Monitoring Committees (I), Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination, Combination Products Timeliness of Premarket Reviews (I), Computerized Systems Used in Clinical Trials (I), Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations, Developing Products for Weight Management Revision 1 (I), Development of Parathyroid Hormone for the Prevention and Treatment of Osteoporosis (I), Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention (I), Drugs, Biologics, and Medical Devices Derived from Bioengineered Plants for Use in Humans and Animals, Estrogen and Estrogen/ Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms - Recommendations for Clinical Evaluation (I), Exercise-Induced Bronchospasm (EIB) - Development of Drugs to Prevent EIB (I), Gingivitis: Development and Evaluation of Drugs for Treatment or Prevention (I), Inhalation Drug Products Packaged in Semipermeable Container Closure Systems (I), Investigational New Drug Applications (INDs)-Determining Whether Human Research Studies Can Be Conducted Without an IND (I), Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs, Malaria: Developing Drug and Nonvaccine Biological Products for Treatment and Prophylaxis (I), OTC Treatment of Herpes Labialis with Antiviral Agents (I), Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval, Pediatric Oncology Studies in Response to a Written Request (I), Preparation of IND Applications for New Drugs Intended for the Treatment of HIV-Infected Individuals, Qualification Process for Drug Development Tools (I), Recommendations for Complying with the Pediatric Rule (I), Sinusitis: Designing Clinical Development Programs of Nonantimicrobial Drugs for Treatment (I), Standards for Clinical Trial Imaging Endpoints, Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials, The Use of Clinical Holds Following Clinical Investigator Misconduct (I), Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro (I), Exposure-Response Relationships - Study Design, Data Analysis, and Regulatory Applications (I), Format and Content of the Human Pharmacokinetics and Bioavailability Section of an Application (I), In Vivo Metabolism/Drug Interaction Studies - Study Design, Data Analysis, and Recommendations for Dosing and Labeling (I), Pharmacokinetics in Patients With Impaired Hepatic Function; Study Design, Data Analysis, and Impact on Dosing and Labeling (I), Pharmacokinetics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling (I), Clinical Lactation Studies - Study Design, Data Analysis and Recommendations for Labeling, Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies, Drug Interaction Studies--Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products (I), Pharmacokinetics in Pregnancy - Study Design, Data Analysis, and Impact on Dosing and Labeling (I), Submission Documentation for Sterilization Process Validation Applications for Human and Veterinary Drug Products (I), Submission of Documentation in Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes (I), Application User Fees for Combination Products, Combination Products Timeliness of Premarket Reviews; Dispute Resolution (I), Coronary Drug-Eluting Stents-Nonclinical and Clinical Studies (I), A Review of FDA's Implementation of the Drug Export Amendments of 1986 (I), Bar Code Label Requirements - Questions and Answers (Revised) (I), Current Good Manufacturing Practice for Phase 1 Investigational Drugs (I), Current Good Manufacturing Practice for Positron Emission Tomography Drug Products (I), Dosage Delivery Devices for Orally Ingested OTC Liquid Drug Products, Expiration Dating and Stability Testing of Solid Oral Dosage Form Drugs Containing Iron (I), Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical Current Good Manufacturing Practices (I), General Principles of Process Validation (I), Good Laboratory Practice Regulations -- Questions and Answers (I), Guidance for Hospitals, Nursing Homes, and Other Health Care Facilities (I), Investigating Out of Specification (OOS) Test Results for Pharmaceutical Production (I), Marketed Unapproved Drugs;Compliance Policy Guide (I), Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography, Monitoring of Clinical Investigations (I), Nuclear Pharmacy Guideline Criteria for Determining When to Register as a Drug Establishment (I), Part 11, Electronic Records, Electronic Signatures - Scope and Application, PET Drugs Current Good Manufacturing Practice (CGMP), Pharmaceutical Components at Risk for Melamine Contamination (I), Pharmacy Compounding --Compliance Policy Guide (I), Possible Dioxin/PCB Contamination of Drug and Biological Products (I), Prescription Drug Marketing Act Regulations for Donation of Prescription Drug Samples to Free Clinics (I), Process Analytical Technology -- A Framework for Innovative Pharmaceutical Manufacturing and Quality Assurance (I), Process Validation: General Principles and Practices, Pyrogen and Endotoxins Testing: Questions and Answers, Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations (I), Sterile Drug Products Produced by Aseptic Processing (I), Testing of Glycerin for Diethylene Glycol (I), The Use of Mechanical Calibration of Dissolution Apparatus 1 and 2 - Good Manufacturing Practice (CGMP) (I), Comparability Protocols -- Protein Drug Products and Biological Products -- Chemistry, Manufacturing, and Controls Information (I), Current Good Manufacturing Practices for Combination Products (I), Current Good Manufacturing Practices for Medical Gases (3rd Revision) (I), Expiration Dating of Unit-Dose Repackaged Drugs: Compliance Policy Guide, Guidance for IRBs, Clinical Investigators, and Sponsors: Exception from Informed Consent Requirements for Emergency Research (I), Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Quality, Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting, Availability (I), Manufacturing, Processing or Holding of Active Pharmaceutical Ingredients (I), Powder Blends and Finished Dosage Units--Stratified In-Process Dosage Unit Sampling and Assessment (I), Repackaging of Solid Oral Dosage Form Drug Products, Drug Safety Information--Food and Drug Administration's Communication to the Public (I), Drug-Induced Liver Injury: Premarketing Clinical Evaluation (I), Medication Guides--Distribution Requirements and Inclusion of Medication Guides in Risk Evaluation and Mitigation Strategies, Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic, Postmarketing Studies and Clinical Trials--Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act, Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets, Classifying Significant Posmarketing Drug Safety Issues, Drug Safety Information -- FDA's Communication to the Public, Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications (I), Safety Labeling Changes; Implementation of the Federal Food, Drug, and Cosmetic Act, Safety Reporting Requirements for INDs (Investigational New Drug Applications) and BA/BE (Bioavailability/Bioequivalence) Studies (I), Providing Electronic Submissions in Electronic Format - ANDAs (I), Providing Regulatory Submissions in Electronic Format -- Content of Labeling (I), Providing Regulatory Submissions in Electronic Format -- Human Pharmaceutical Product Applications and Related Submissions (I), Regulatory Submissions in Electronic Format; General Considerations (I), Regulatory Submissions in Electronic Format; NDAs (I), SPL Standard for Content of Labeling Technical Qs & As (I), Compliance Policy on Reporting Drug Sample Distribution Information, Providing Regulatory Submissions in Electronic Format -- Annual Reports for New DrugApplications and Abbreviated New Drug Applications (I), Providing Regulatory Submissions in Electronic Format--General Considerations (I), Providing Regulatory Submissions in Electronic Format - Postmarketing Expedited Safety Reports (I), Providing Regulatory Submissions in Electronic Format - Postmarketing Individual Case Safety Reports (I), Providing Regulatory Submissions in Electronic Format -- Postmarketing Periodic Adverse Drug Experience Reports (I), Providing Regulatory Submissions in Electronic Format - Prescription Drug Advertising and Promotional Labeling (I), Providing Regulatory Submissions in Electronic Format--Receipt Date (I), Providing Submissions in Electronic Format -- Standardized Study Data, 180-Day Exclusivity When Multiple Abbreviated New Drug Applications Are Submitted on the Same Day (I), Abbreviated New Drug Applications: Impurities in Drug Products, Alternate Source of Active Pharmaceutical Ingredients in Pending ANDAs (I), ANDAs: Impurities in Drug Substances; Chemistry, Manufacturing and Controls Information (I), ANDAs: Pharmaceutical Solid Polymorphism; Chemistry, Manufacturing and Controls Information (I), Court Decisions, ANDA Approvals, and 180-Day Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act (I), Handling and Retention of Bioavailability and Bioequivalence Testing Samples (I), Individual Product Bioequivalence Recommendations - List of Product Bioequivalence Recommendations (I), Letter announcing that the OGD will now accept the ICH long-term storage conditions as well as the stability studies conducted in the past (I), Letter describing efforts by the CDER & the ORA to clarify the responsibilities of CDER chemistry review scientists and ORA field investigators in the new & abbreviated drug approval process in order to reduce duplication or redundancy in the process (I), Letter on incomplete Abbreviated Applications, Convictions Under GDEA, Multiple Supplements, Annual Reports for Bulk Antibiotics, Batch Size for Transdermal Drugs, Bioequivalence Protocols, Research, Deviations from OGD Policy (I), Letter on the provision of new information pertaining to new bioequivalence guidelines and refuse-to-file letters (I), Letter on the provision of new procedures and policies affecting the generic drug review process (I), Letter on the request for cooperation of regulated industry to improve the efficiency and effectiveness of the generic drug review process, by assuring the completeness and accuracy of required information and data submissions (I), Letter on the response to 12/20/84 letter from the Pharmaceutical Manufacturers Association about the Drug Price Competition and Patent Term Restoration Act (I), Letter to all ANDA and AADA applicants about the Generic Drug Enforcement Act of 1992 (GDEA), and the Office of Generic Drugs intention to refuse-to-file incomplete submissions as required by the new law (I), Letter to regulated industry notifying interested parties about important detailed information regarding labeling, scale-up, packaging, minor/major amendment criteria, and bioequivalence requirements (I), Major, Minor, and Telephone Amendments to Abbreviated New Drug Applications (I), Potassium Chloride Modified-Release Tablets and Capsules: In Vivo Bioequivalence and In Vitro Dissolution Testing (I), Revising ANDA Labeling Following Revision of the RLD Labeling (I), Submission of Summary Bioequivalence Data for Abbreviated New Drug Applications (I), Variations in Drug Products that May Be Included in a Single ANDA (I), Listed Drugs, 30-Month Stays, and Approval of ANDAs and 505 (b)(2) Applications Under Hatch Waxman, as Amended by the Medicare Prescription Drug Improvement, and Modernization Act of 2003 - Questions and Answers (I), Generic Drug User Fee Amendments of 2012: Questions and Answers, Self-Identification of Generic Drug Facilities, Sites, and Organizations, ANDAs: Stability Testing of Drug Substances and Products, Good Review Management Principles for Prescription Drug User Fee Act Products (I), Pharmacology/Toxicology Review Format (I), E1A - The Extent of Population Exposure to Assess Clinical Safety: for Drugs Intended for Long Term Treatment of Non-Life-Threatening Conditions (I), E2A - Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (I), E2B - Data Elements for Transmission of Individual Case Safety Reports (I), E2B(M) - Data Elements for Transmission of Individual Case Safety Reports (Revised) (I), E2B(M): Data Elements for Transmission of Individual Case Safety Reports -- Questions and Answers (Revision 2) (I), E2C - Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs (I), E2C Addendum - Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs (I), E3 - Structure and Content of Clinical Study Reports (I), E4 - Dose-Response Information to Support Drug Registration (I), E5 - Ethnic Factors in the Acceptability of Foreign Clinical Data (I), E5 - Ethnic Factors in the Acceptability of Foreign Clinical Data, Questions and Answers (I), E6 - Good Clinical Practice: Consolidated Guideline (I), E7 - Studies in Support of Special Populations: Geriatrics (I), E7 Studies in Support of Special Populations; Geriatrics; Questions and Answers, E8 - General Considerations for Clinical Trials (I), E9 - Statistical Principles for Clinical Trials (I), E10 - Choice of Control Group and Related Issues in Clinical Trials (I), E11 - Clinical Investigation of Medicinal Products in the Pediatric Population (I), E14 - Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non Antiarrhythmic Drugs (I), E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non Antiarrhythmic Drugs.
Best Banned Pre Workouts,
Articles F
fda guideline for the monitoring of clinical investigations
